Prolonged efficacy of Bifidobacterium lactis in the treatment of functional dyspepsia
Qi Zhang,Guang Li,Wen Zhao,Limian Zhou,Xiaoxu Zhang,Jingjing He,Peng An,Yinghua Liu,Chengying Zhang,Yong Zhang,Simin Liu,Wei-Hsien Liu,Fudong Liu,Yixuan Li,Wenjian Jiang,Xifan Wang,Xiaoyu Wang,Qingyu Wang,Bing Fang,Meng Guo,Yuyang Zhao,Yimei Ren,Xiaokang Niu,Dongjie Li,Chao Zhang,Shaoqi Shi,Ran Wang,Xinjuan Liu,Wei-Lian Hung,Fazheng Ren
DOI: https://doi.org/10.21203/rs.3.rs-2529681/v1
2023-01-01
Abstract:Abstract Background Current treatment for functional dyspepsia (FD) has limited and unsustainable efficacy. Probiotics have the potential to alleviate FD; However, the underlying mechanism remains unclear. This study aimed to evaluate the effect and mechanism of probiotics in alleviating FD. Methods A randomized, positive-drug and placebo-controlled clinical trial was conducted; 200 FD patients were randomly divided into four groups (placebo, positive control [proton pump inhibitors, PPI] or Bifidobacterium lactis BL-99 [low, high doses]). The clinical response rates in 8-week treatment, 2-week follow-up and 6-week questionnaire survey periods were recorded. Faecal microbiota and metabolites were assessed by metagenomics, un-target and target metabolomics technology. Results The clinical response rate for BL-99_high [43 (95.6%) of 45] group was significantly higher than that for placebo [28 (62.2%) of 45, P = 0.001], BL-99_low [36 (76.6%) of 47, P = 0.019] or positive control group [34 (70.8%) of 48, P = 0.006] after an 8-week treatment. In particular, BL-99_high group was still higher than that for placebo or positive control group after 2-week follow-up and 6-week questionnaire survey periods. Further metagenomic and metabolomics studies found that PPI significantly decreased the gut microbiota diversity, induced the cluster of Escherichia enterotype and decreased butyrate contents. Interestingly, BL-99 converted the gut microbiota enterotype from Bacteroidetes ( Alistipes finegoldii , Alistipes shahii ) to Firmicutes c ( Roseburia intestinalis , Roseburia inulinivorans ) and Escherichia enterotype was not clustered after 8-week treatment, which activates carbohydrate esterase activity, and increases faecal and serum butyrate levels. Conclusion BL-99 sustainably alleviated FD symptoms by altering the taxonomic composition and functional potential of the FD microbiome. Trial registration Chictr.org.cn ChiCTR2000041430.